Spyre Therapeutics (SYRE) EPS (Weighted Average and Diluted) (2020 - 2026)
Spyre Therapeutics posted quarterly EPS (Weighted Average and Diluted) of -$0.74 for Q1 2026, up 96.91% year-on-year from -$0.38 in Q1 2025, and little changed on a QoQ basis from -$0.74 in Q4 2025.
Spyre Therapeutics (SYRE) has 7 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.74 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 96.91% year-over-year to -$0.74; the trailing twelve-month figure through Mar 2026 stood at -$7.94 (up 93.45% YoY), and the FY2025 full-year result was -$1.98, up 98.44% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.74, roughly flat from -$0.74 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $40.14 in Q2 2023 and bottomed at -$564.94 in Q4 2023.
- The 5-year median for EPS (Weighted Average and Diluted) is -$4.84 (2022), against an average of -$39.55.
- The widest annual swing landed in 2023, when EPS (Weighted Average and Diluted) soared 14966.67%; it then slumped 5009.3% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $20.17 in 2022, then plunged by 2900.89% to -$564.94 in 2023, then surged by 94.42% to -$31.53 in 2024, then jumped by 97.65% to -$0.74 in 2025, then changed by 0.0% to -$0.74 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.74 (Q1 2026), -$0.74 (Q4 2025), and -$5.97 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | -0.74 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.74 |
| Dec 31, 2025 | -0.74 |
| Sep 30, 2025 | -5.97 |
| Jun 30, 2025 | -0.49 |
| Mar 31, 2025 | -23.95 |
| Dec 31, 2024 | -31.53 |
| Sep 30, 2024 | -42.22 |
| Jun 30, 2024 | -23.61 |
| Mar 31, 2024 | -28.93 |
| Dec 31, 2023 | -564.94 |
| Sep 30, 2023 | 0.86 |
| Jun 30, 2023 | 40.14 |
| Mar 31, 2023 | -4.89 |
| Dec 31, 2022 | 20.17 |
| Sep 30, 2022 | -4.84 |
| Jun 30, 2022 | -0.27 |
| Mar 31, 2022 | -0.37 |
| Dec 31, 2021 | -24.33 |
| Sep 30, 2021 | -0.31 |
| Jun 30, 2021 | -0.10 |
| Dec 31, 2020 | -0.43 |